Merck’s COVID-19 drug to be reviewed by U.S. FDA advisers- Bloomberg News

Published by

(Reuters) -The U.S. Food and Drug Administration will send drugmaker Merck & Co’s experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans. The advisory committee will weigh in on molnupiravir’s safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report said. Merck earlier this week said it filed for U.S. emergency use authorization for molnupiravir to treat mild-to-moderate patients of COVID-19, …

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *